Aggressive Lymphomas
News
ASH expands late-breaking abstract session
An additional presentation has been added to the late-breaking abstract session of the 2018 ASH Annual Meeting. The session was expanded from six...
News
CAR T-cell studies to be presented at ASH
Several studies set to be presented at the 2018 ASH Annual Meeting provide new insights regarding chimeric antigen receptor (CAR) T-cell therapies...
Conference Coverage
ASH 2018 coming attractions look at the big picture
Big trials, big results in malignant and nonmalignant hematologic disorders are on the program at the 2018 ASH annual meeting.
News
Biosimilar deemed equivalent to rituximab in FL
Phase 3 results suggest the biosimilar product CT-P10 is equivalent to rituximab in patients with low-tumor-burden follicular lymphoma (FL)....
News
Elderly NHL patients have higher NRM after HSCT
A retrospective study suggests elderly patients with non-Hodgkin lymphoma (NHL) are more likely to die, but not relapse, within a year of...
News
Bortezomib may overcome resistance in WM
Bortezomib may help overcome treatment resistance in patients with Waldenström’s macroglobulinemia (WM) and CXCR4 mutations, according to a new...
News
FDA expands approval of brentuximab vedotin to PTCL
This is the first FDA approval of a treatment for newly-diagnosed PTCL.
News
R-CHOP effective as first-line treatment in FL
Long-term data suggest R-CHOP can be effective as first-line treatment for patients with follicular lymphoma (FL). In a phase 2-3 trial,...
From the Journals
NHL patients report fear, isolation during chemo
The qualitative study found that patients reported feeling like they were on an “emotional roller coaster” during their treatment.
Conference Coverage
Relapsed MCL: Options for treatment
There are a number of treatment options for relapsed MCL, but BTK inhibitors are particularly useful.
News
FDA puts selinexor on fast track for DLBCL
Selinexor has received fast track designation to treat patients with previously treated DLBCL who are not eligible for certain therapies.